Dr Reddy's Laboratories (UK) Ltd v Eli Lilly & Company Ltd [2009] EWCA Civ 1362 (18 December 2009)

Dr Reddy's Laboratories (UK) Ltd v Eli Lilly & Company Ltd [2009] EWCA Civ 1362 (18 December 2009)

The patent for olanzapine is valid because the prior art did not specifically disclose or make obvious the compound; the selection of olanzapine was not arbitrary but represented a real technical advance, supported by experimental and clinical evidence. The attacks based on lack of novelty, obviousness, and insufficiency all fail.

Citation
[2009] EWCA Civ 1362
Parties
Claimant/appellant: Dr Reddy's Laboratories (UK) Limited; Defendant/respondent: Eli Lilly and Company Limited
Jurisdiction
England and Wales
Judgment Date
18 December 2009
Procedural Posture
Patent Revocation Appeal / Court of Appeal Judgment on Appeal From High Court (patents Court)
Outcome
Appeal dismissed; patent upheld as valid.
Legal Topics
Patent Validity, Novelty, Obviousness, Selection Patents, Pharmaceutical Patents
Intellectual Property Patents Patent Validity Novelty Obviousness Selection Patents Pharmaceutical Patents

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 13 Party arguments 2
Sign in to unlock

Parties

Dr Reddy's Laboratories (UK) Limited

Claimant/appellant

Eli Lilly and Company Limited

Defendant/respondent

Procedural Posture

Patent Revocation Appeal / Court of Appeal Judgment on Appeal From High Court (patents Court)

Legal Issues

  1. 1 Whether Eli Lilly's patent for olanzapine lacks novelty over prior art (British Patent 1,533,235)
  2. 2 Whether the patent is obvious over prior art (British Patent 1,533,235 and Chakrabarti 1980)
  3. 3 Whether the patent is invalid for insufficiency

Ratio Decidendi

The patent for olanzapine is valid because the prior art did not specifically disclose or make obvious the compound; the selection of olanzapine was not arbitrary but represented a real technical advance, supported by experimental and clinical evidence. The attacks based on lack of novelty, obviousness, and insufficiency all fail.

Court Disposition

Appeal dismissed; patent upheld as valid.

Orders

  • Dr Reddy's Laboratories' appeal is dismissed.
  • Eli Lilly's patent for olanzapine is upheld as valid.